FTC Solar Upgraded to Buy by UBS as New Trackers Gain Orders
UBS says a depressed valuation misses earnings power from revamped 1P and First Solar trackers.
Already have an account? Sign in.
UBS says a depressed valuation misses earnings power from revamped 1P and First Solar trackers.
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
Company also announces Rhode Island acquisition plus Amazon, Google nuclear deals.
Be the first to know when deals break, stocks move, or biotech headlines hit.